Skip to main content
. Author manuscript; available in PMC: 2015 May 15.
Published in final edited form as: J Immunol. 2014 Apr 9;192(10):4748–4757. doi: 10.4049/jimmunol.1303190

Figure 1. The HPV16 L2108-126 peptide reduces binding of HPV16L1L2 VLP and binds to A2t on LC.

Figure 1

A. LC were left untreated or were treated with the L2108-126 or scrambled peptide and subsequently incubated with HPV16L1L2 VLP. After washing, HPV16L1L2 VLP remaining on the surface of LC were detected using an L1 specific conformational antibody (H16.V5). Binding was assessed by flow cytometry. These data are expressed as the mean of three separate experiments ± SEM (*P < 0.05 as determined by a two-tailed, unpaired t-test, as compared to untreated LC). B. LC were incubated with either no peptide or (6x)His-L2108-126 peptide and subsequently cross-linked with DTSSP. Cells were then lysed and mixed with a Ni-NTA agarose slurry overnight and eluted. Eluates were then electrophoresed, transferred to nitrocellulose and probed with either an anti-AnxA2 or an anti-S100A10 antibody. One representative experiment of three is shown.